315 related articles for article (PubMed ID: 34243075)
1. Optimization of pyrazole-based compounds with 1,2,4-triazole-3-thiol moiety as selective COX-2 inhibitors cardioprotective drug candidates: Design, synthesis, cyclooxygenase inhibition, anti-inflammatory, ulcerogenicity, cardiovascular evaluation, and molecular modeling studies.
Abdellatif KRA; Abdelall EKA; Elshemy HAH; Philoppes JN; Hassanein EHM; Kahk NM
Bioorg Chem; 2021 Sep; 114():105122. PubMed ID: 34243075
[TBL] [Abstract][Full Text] [Related]
2. New 1,2,4-triazole/pyrazole hybrids linked to oxime moiety as nitric oxide donor celecoxib analogs: Synthesis, cyclooxygenase inhibition anti-inflammatory, ulcerogenicity, anti-proliferative activities, apoptosis, molecular modeling and nitric oxide release studies.
Fadaly WAA; Elshaier YAMM; Hassanein EHM; Abdellatif KRA
Bioorg Chem; 2020 May; 98():103752. PubMed ID: 32197148
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and pharmacological evaluation of novel and selective COX-2 inhibitors based on celecoxib scaffold supported with in vivo anti-inflammatory activity, ulcerogenic liability, ADME profiling and docking study.
Abdellatif KRA; Abdelall EKA; Elshemy HAH; Philoppes JN; Hassanein EHM; Kahk NM
Bioorg Chem; 2022 Mar; 120():105627. PubMed ID: 35065465
[TBL] [Abstract][Full Text] [Related]
4. New pyridazine derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents; design, synthesis and biological evaluation.
Ahmed EM; Hassan MSA; El-Malah AA; Kassab AE
Bioorg Chem; 2020 Jan; 95():103497. PubMed ID: 31838289
[TBL] [Abstract][Full Text] [Related]
5. COX-1/COX-2 inhibition assays and histopathological study of the new designed anti-inflammatory agent with a pyrazolopyrimidine core.
Abdelall EKA; Lamie PF; Ahmed AKM; El-Nahass ES
Bioorg Chem; 2019 May; 86():235-253. PubMed ID: 30716621
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of novel halogenated triarylpyrazoles as selective COX-2 inhibitors: Anti-inflammatory activity, histopatholgical profile and in-silico studies.
Abdellatif KRA; Abdelall EKA; Labib MB; Fadaly WAA; Zidan TH
Bioorg Chem; 2020 Dec; 105():104418. PubMed ID: 33166844
[TBL] [Abstract][Full Text] [Related]
7. New methyl 5-(halomethyl)-1-aryl-1H-1,2,4-triazole-3-carboxylates as selective COX-2 inhibitors and anti-inflammatory agents: Design, synthesis, biological evaluation, and docking study.
Li SM; Tsai SE; Chiang CY; Chung CY; Chuang TJ; Tseng CC; Jiang WP; Huang GJ; Lin CY; Yang YC; Fuh MT; Wong FF
Bioorg Chem; 2020 Nov; 104():104333. PubMed ID: 33142408
[TBL] [Abstract][Full Text] [Related]
8. Ligand based design and synthesis of pyrazole based derivatives as selective COX-2 inhibitors.
Murahari M; Mahajan V; Neeladri S; Kumar MS; Mayur YC
Bioorg Chem; 2019 May; 86():583-597. PubMed ID: 30782576
[TBL] [Abstract][Full Text] [Related]
9. Non-acidic 1,3,4-trisubstituted-pyrazole derivatives as lonazolac analogs with promising COX-2 selectivity, anti-inflammatory activity and gastric safety profile.
Abdellatif KRA; Fadaly WAA; Elshaier YAMM; Ali WAM; Kamel GM
Bioorg Chem; 2018 Apr; 77():568-578. PubMed ID: 29475165
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, biological evaluation and docking analysis of 3-methyl-1-phenylchromeno[4,3-c]pyrazol-4(1H)-ones as potential cyclooxygenase-2 (COX-2) inhibitors.
Grover J; Kumar V; Sobhia ME; Jachak SM
Bioorg Med Chem Lett; 2014 Oct; 24(19):4638-4642. PubMed ID: 25219899
[TBL] [Abstract][Full Text] [Related]
11. Novel tetrazole-based selective COX-2 inhibitors: Design, synthesis, anti-inflammatory activity, evaluation of PGE
Labib MB; Fayez AM; El-Nahass ES; Awadallah M; Halim PA
Bioorg Chem; 2020 Nov; 104():104308. PubMed ID: 33011534
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of pyridazinone derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents.
Ahmed EM; Kassab AE; El-Malah AA; Hassan MSA
Eur J Med Chem; 2019 Jun; 171():25-37. PubMed ID: 30904755
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, Anti-Inflammatory Activity, and COX-1/2 Inhibition Profile of Some Novel Non-Acidic Polysubstituted Pyrazoles and Pyrano[2,3-c]pyrazoles.
Faidallah HM; Rostom SAF
Arch Pharm (Weinheim); 2017 May; 350(5):. PubMed ID: 28370254
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and mechanistic study of novel diarylpyrazole derivatives as anti-inflammatory agents with reduced cardiovascular side effects.
Amin NH; Hamed MIA; Abdel-Fattah MM; Abusabaa AHA; El-Saadi MT
Bioorg Chem; 2021 Nov; 116():105394. PubMed ID: 34619468
[TBL] [Abstract][Full Text] [Related]
15. Novel 1,5-diaryl pyrazole-3-carboxamides as selective COX-2/sEH inhibitors with analgesic, anti-inflammatory, and lower cardiotoxicity effects.
Hendawy OM; Gomaa HAM; Alzarea SI; Alshammari MS; Mohamed FAM; Mostafa YA; Abdelazeem AH; Abdelrahman MH; Trembleau L; Youssif BGM
Bioorg Chem; 2021 Nov; 116():105302. PubMed ID: 34464816
[TBL] [Abstract][Full Text] [Related]
16. 1-(4-Methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-3-carboxamides: synthesis, molecular modeling, evaluation of their anti-inflammatory activity and ulcerogenicity.
Abdel-Aziz M; Beshr EA; Abdel-Rahman IM; Ozadali K; Tan OU; Aly OM
Eur J Med Chem; 2014 Apr; 77():155-65. PubMed ID: 24631895
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, evaluation and molecular modelling studies of some novel 5,6-diphenyl-1,2,4-triazin-3(2H)-ones bearing five-member heterocyclic moieties as potential COX-2 inhibitors: A hybrid pharmacophore approach.
Banerjee AG; Das N; Shengule SA; Sharma PA; Srivastava RS; Shrivastava SK
Bioorg Chem; 2016 Dec; 69():102-120. PubMed ID: 27750057
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of new 1,5-diarylpyrazole derivatives.
Abdellatif KR; Fadaly WA; Ali WA; Kamel GM
J Enzyme Inhib Med Chem; 2016; 31(sup3):54-60. PubMed ID: 27541738
[TBL] [Abstract][Full Text] [Related]
19. New indomethacin analogs as selective COX-2 inhibitors: Synthesis, COX-1/2 inhibitory activity, anti-inflammatory, ulcerogenicity, histopathological, and docking studies.
Abdellatif KRA; Abdelall EKA; Elshemy HAH; El-Nahass ES; Abdel-Fattah MM; Abdelgawad YYM
Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000328. PubMed ID: 33314237
[TBL] [Abstract][Full Text] [Related]
20. Cyclic enaminone as new chemotype for selective cyclooxygenase-2 inhibitory, anti-inflammatory, and analgesic activities.
Kumar R; Saha N; Purohit P; Garg SK; Seth K; Meena VS; Dubey S; Dave K; Goyal R; Sharma SS; Banerjee UC; Chakraborti AK
Eur J Med Chem; 2019 Nov; 182():111601. PubMed ID: 31445233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
